✦ LIBER ✦

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

✍ Scribed by Aogi, Kenjiro; Saeki, Toshiaki; Nakamura, Seigo; Kashiwaba, Masahiro; Sato, Nobuaki; Masuda, Norikazu; Rai, Yoshiaki; Ohno, Shinji; Kuroi, Katsumasa; Nishimura, Reiki; Miyakoda, Keiko; Akiyama, Futoshi; Kurosumi, Masafumi; Ikeda, Tadashi

Book ID: 121629416
Publisher: Springer
Year: 2012
Tongue: English
Weight: 329 KB
Volume: 18
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-012-0437-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of liposome-encapsulated

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

✍ Saracchini, S.; Foltran, L.; Tuccia, F.; Bassini, A.; Sulfaro, S.; Micheli, E.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 548 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB

Trastuzumab plus docetaxel with or witho

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Neoadjuvant treatment of HER2 overexpres

Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”

✍ M. Untch; M. Rezai; S. Loibl; P.A. Fasching; J. Huober; H. Tesch; I. Bauerfeind; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A phase II study of metronomic paclitaxe

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

✍ Masuda, N.; Higaki, K.; Takano, T.; Matsunami, N.; Morimoto, T.; Ohtani, S.; Miz 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 519 KB